Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Migraine: later-stage trial registry
40 of 105 indexed Migraine trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #125 of 28,707 conditions by registered trial count.
105 US clinical trials · 40 currently recruiting · #125 of 28,707 conditions by registered trial count
Migraine: 105 US clinical trials tracked, 40 recruiting.
Migraine is the subject of 105 registered US clinical trials on ClinicalTrials.gov, 40 of them currently open to new participants. 33 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 7 of these trials.
Enrollment posture brief
Registry condition migraine
OPEN 40 | RECR 38% | LATE 33 | EARLY 20 | RANK #125 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Behavior, Health (38% recruiting · 21 trials)
Migraine lists 40 open slots (38% of 105 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Migraine on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Migraine recruits in line with its size-band peers.
40 of 105 indexed trials (38.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Migraine trials is spread across many organizations.
Pfizer accounts for 7 of 105 trials (6.7%). 59 distinct sponsors appear on at least one study for this condition label.
-
Typical Migraine enrolment sits around 127 participants.
Median target enrolment is 127 among the 103 trials that report a genuine target (sentinel values excluded). 42 of those (40.8%) plan for fewer than 100 participants.
-
Migraine research is mostly interventional.
85 interventional and 20 observational studies make up this index (81% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
105 total, page 1 of 3
Aimovig Pregnancy Exposure Registry
Amgen
NCT06150781
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
AbbVie
NCT05158894
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
Mayo Clinic
NCT06972056
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
National Institute of Mental Health (NIMH)
NCT05669703
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
NCT05125302
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
AbbVie
NCT06543914
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Pfizer
NCT05046613
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Hospital Universitari Vall d'Hebron Research Institute
NCT07159750
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Pfizer
NCT05156398
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S
NCT05164172
External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
Cefaly Technology
NCT06788977
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie
NCT06417775
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
AbbVie
NCT06602479
Overlapping Pain Trajectory Study
Children's Hospital Medical Center, Cincinnati
NCT05752396
Responding With Evidence and Access for Childhood Headaches
Children's Hospital Medical Center, Cincinnati
NCT05889624
RELAXaHEAD for Headache Patients (Phase III)
NYU Langone Health
NCT06077838
BE WELL With Migraine: Brain Education and WELLness With Migraine
Wake Forest University Health Sciences
NCT05987592
Mind Body Balance for Pediatric Migraine
Children's Hospital Medical Center, Cincinnati
NCT04715685
Migraine in Adolescents
Washington University School of Medicine
NCT05654012
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Pfizer
NCT06616194
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
Mayo Clinic
NCT06401642
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
Yale University
NCT06624137
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
AbbVie
NCT07310290
Migraine Manager (R01)
Children's Hospital Medical Center, Cincinnati
NCT04567355
Endometriosis and Migraine
Washington University School of Medicine
NCT06785129
Objectively Diagnose and Monitor Treatment of Light Sensitivity
Randy Kardon
NCT03694626
Cocoa Extract for Migraine Trial
Brigham and Women's Hospital
NCT06808230
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
Wake Forest University Health Sciences
NCT06904287
Investigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli
University of Minnesota
NCT06961864
Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?
Texas Tech University Health Sciences Center, El Paso
NCT06016465
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
Antonios Likourezos
NCT06473597
MMA Embolization for Refractory Chronic Migraine
Cerenovus, Part of DePuy Synthes Products
NCT06735833
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
Uniformed Services University of the Health Sciences
NCT07267819
Determining the Utility of a Behavioral Intervention in Chronic Migraine
Mayo Clinic
NCT05415020
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
Medstar Health Research Institute
NCT07301008
Mechanistic Studies of Psilocybin in Headache Disorders
Yale University
NCT06464367
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
Northwell Health
NCT07061847
Emgality for Migraine in Breastmilk
University of California, San Francisco
NCT06085144
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
Stanford University
NCT04930887
Stimulation of External Carotid Artery Circulation
The University of Texas Medical Branch, Galveston
NCT07402954
Nerivio Efficacy Under High-Frequency Use
Theranica
NCT07336056
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
H. Lundbeck A/S
NCT06323928
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Amgen
NCT03836040
Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study
Theranica
NCT07487701
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
H. Lundbeck A/S
NCT06701526
Treatment for Migraine and Mood
Amanda Shallcross
NCT05576467
Puberty, Sex Hormones and Pain Sensitivity in Adolescents With Migraine
Washington University School of Medicine
NCT05738213
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
Brigham and Women's Hospital
NCT06173661
Omega-3 Supplementation for Pediatric Migraine
University of North Carolina, Chapel Hill
NCT06899074
A Study to Evaluate White Matter Hyperintensities in Migraine
Mayo Clinic
NCT05112289
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 12 |
| Phase 3 | 20 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Migraine records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Migraine trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Migraine page
105 registered trials, 40 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 40 Migraine trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Migraine trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Migraine condition card totals 105 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.